Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib in Anemic Myelofibrosis (REALISE)
NCT02966353Phase 2Completed
- Sponsor
- Novartis
- Start
- Mar 2017
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 2, open-label, single-arm trial of ruxolitinib in myelofibrosis (MF), sponsored by Novartis. Primary endpoint: Percentage of Participants With at Least 50% Reduction in Spleen Length From Baseline at 24 weeks. Started Mar 2017; status: completed.
02
Drugs
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT02966353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02966353.